InnoCentive.com (A) Custom Case Solution & Analysis

Evidence Brief: InnoCentive.com (A)

Prepared by: Business Case Data Researcher

1. Financial Metrics

• Initial Funding: Eli Lilly provided 25 million USD in seed capital for the launch of the platform (Paragraph 4).
• Seeker Fees: Posting a challenge costs between 10,000 USD and 15,000 USD per contract (Exhibit 1).
• Success Fees: InnoCentive charges a commission ranging from 40 percent to 100 percent of the award amount paid to the solver (Exhibit 1).
• Award Ranges: Cash prizes for successful solutions vary from 5,000 USD to 100,000 USD (Paragraph 12).
• Revenue Model: Income is generated through a combination of upfront posting fees and back-end success fees (Paragraph 15).

2. Operational Facts

• Solver Network: 25,000 scientists from 175 countries are registered on the platform (Paragraph 1).
• Challenge Success Rate: Approximately 30 percent of posted challenges receive a solution that meets the requirements of the seeker (Paragraph 18).
• Personnel: The venture began with 8 full-time employees in 2001 (Paragraph 6).
• Intellectual Property: The platform uses a specific legal framework to transfer ownership of the solution from the solver to the seeker upon payment (Paragraph 22).
• Anonymity: The identity of the seeker remains hidden from the solver during the competition to protect trade secrets (Paragraph 24).

3. Stakeholder Positions

• Alpheus Bingham: President of InnoCentive. He views the platform as a way to access the global scientific brain trust and reduce R and D costs (Paragraph 5).
• Eli Lilly and Company: The parent organization and primary financier. They seek to externalize innovation but also face internal resistance from scientists (Paragraph 8).
• Seekers: Large corporations like Dow Chemical and Procter and Gamble. They require high-quality solutions but worry about sharing sensitive problem details (Paragraph 26).
• Solvers: Independent scientists, retirees, and academics. They are motivated by financial rewards and the prestige of solving difficult problems (Paragraph 30).

4. Information Gaps

• Marketing Costs: The case does not provide the specific cost to acquire a single registered solver.
• Solver Demographics: Precise data on the employment status or institutional affiliation of the 25,000 solvers is missing.
• Profitability Timeline: The document lacks a projected date for the venture to reach a break-even point.

Strategic Analysis

Prepared by: Market Strategy Consultant

1. Core Strategic Question

• How can InnoCentive transition from a corporate experiment into a neutral and scalable global marketplace for scientific innovation?
• Can the platform overcome the inherent conflict of interest caused by its ownership by Eli Lilly to attract direct competitors?

2. Structural Analysis

The platform operates as a two-sided market where the value to one group increases as the size of the other group grows. Currently, the network effects are nascent but fragile. The primary barrier is the high cost of entry for Seekers, who must invest significant time to frame problems correctly. Applying the Value Chain lens reveals that InnoCentive is attempting to outsource the most expensive part of the R and D process: the ideation and initial proof of concept. The competitive rivalry is low in the open innovation space, but the threat of substitutes is high, as companies can continue to rely on internal R and D or traditional consulting firms.

3. Strategic Options

Option 1: Horizontal Expansion into Engineering and Computer Science
Expand the challenge categories beyond chemistry and biology. This broadens the solver base and attracts seekers from the technology and manufacturing sectors.
Trade-offs: Dilutes the specialized focus of the platform but increases the total addressable market.
Resources: Requires new subject matter experts to vet challenges in unfamiliar fields.

Option 2: Deepen the Life Sciences Niche
Focus exclusively on becoming the primary clearinghouse for pharmaceutical and chemical problems.
Trade-offs: Limits growth potential but builds high barriers to entry through specialized IP protocols.
Resources: Requires deeper integration with the internal labs of the seekers.

4. Preliminary Recommendation

InnoCentive should pursue horizontal expansion. The current success rate of 30 percent suggests that cross-pollination of ideas from different scientific fields is the primary driver of value. A chemist might solve a problem that has baffled biologists for years. To achieve this, the platform must diversify its seeker base to include non-life-science industries immediately.

Implementation Roadmap

Prepared by: Operations and Implementation Planner

1. Critical Path

• Month 1: Standardize the Challenge Definition Process. The bottleneck is the inability of seekers to write clear problems. Develop a template that reduces the time required to post a challenge by 50 percent.
• Month 2: Expand the Sales Force. Hire five account managers with backgrounds in engineering and physics to target the aerospace and automotive sectors.
• Month 3: Launch a Solver Engagement Program. Implement a tiered solver system where high-performers get early access to challenges to ensure a higher initial response rate.

2. Key Constraints

• IP Transfer Friction: Different industries have different standards for patent transfer. The legal team must create modular contracts for various jurisdictions.
• Not Invented Here Syndrome: Internal R and D teams at seeker companies often view InnoCentive as a threat to their jobs. Implementation requires a change management program for seeker executives.

3. Risk-Adjusted Implementation Strategy

The plan assumes a 20 percent increase in challenge volume per quarter. If this target is missed, the sales team will pivot to a subscription model for seekers, providing a steady cash flow regardless of challenge success. This contingency ensures the platform remains operational even if the success rate fluctuates during the expansion into new scientific domains.

Executive Review and BLUF

Prepared by: Senior Partner and Executive Reviewer

1. BLUF

InnoCentive must spin off from Eli Lilly to become a credible neutral party. The current ownership structure prevents direct competitors from trusting the platform with their most sensitive R and D problems. Success depends on horizontal expansion and a shift toward a subscription-based revenue model to stabilize cash flow. The platform is a volume business; without a massive increase in seekers, the 30 percent success rate will not sustain the 25 million USD investment. Execute a full corporate separation within 12 months to unlock the next phase of growth.

2. Dangerous Assumption

The analysis assumes that the 25,000 solvers will remain active without a guaranteed return on their time. If the success rate stays at 30 percent, 70 percent of solver effort is wasted. This labor model is precarious. If a competitor platform offers a participation fee, the solver base will migrate instantly.

3. Unaddressed Risks

• Regulatory Scrutiny: As the platform grows, the transfer of sensitive chemical or biological data across borders may trigger national security reviews. Probability: Medium. Consequence: High.
• Quality Dilution: Rapid expansion into engineering may attract low-quality solvers, reducing the success rate and damaging the brand of the platform. Probability: High. Consequence: Medium.

4. Unconsidered Alternative

The team failed to consider a White-Label Software-as-a-Service model. Instead of managing a public marketplace, InnoCentive could sell its platform technology to large firms to manage their own internal and partner-only innovation challenges. This would remove the IP risks and the conflict of interest issues while providing high-margin recurring revenue.

5. Final Verdict

REQUIRES REVISION. The Strategic Analyst must incorporate the White-Label SaaS model as a third option and evaluate its impact on the long-term valuation of the company. Once this alternative is assessed, the package will be ready for leadership review.